Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.

JAMA oncology - 1 Jun 2017

Agarwal Neeraj, Hahn Andrew W, Gill David M, Farnham James M, Poole Austin I, Cannon-Albright Lisa

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Kaplan-Meier Estimate
Share to Multienzyme Complexes
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenomic Variants

Share to Prostatectomy

Share to Prostatic Neoplasms

Share to Steroid Isomerases

Source

Open in PubMed Open full text

Identifiers

PMID: 28208175
DOI: 10.1001/jamaoncol.2017.0147
PMCID: PMC5824318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.PMID 28208175Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

Germline HSD3B1 Genetics and Prostate Cancer OutcomesSemantic proximity Read ↗

HSD3B1 genotype predicts castration resistance.Semantic proximity Read ↗

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity Read ↗

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Semantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.Semantic proximity Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.Semantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT.Semantic proximity Read ↗

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.